Integrative role of vitamin D related and Interleukin-28B genes polymorphism in predicting treatment outcomes of Chronic Hepatitis C

M. O. El-Derany; N. M. Hamdy; N. L. Al-Ansari; H. O. El-Mesallamy

doi:10.1186/s12876-016-0440-5

Table 4 Baseline clinical characteristics of HCV-infected F1, F2 and F3 patients

From: Integrative role of vitamin D related and Interleukin-28B genes polymorphism in predicting treatment outcomes of Chronic Hepatitis C

Characteristics	SVR	NR	P value	Statistics (univariate)
Characteristics	(n = 49)	(n = 57)	P value	OR(95%CI)
Age mean ± SD (years)	50.2 ± 8.5	49.3 ± 7.9	-
Gender distribution[n(%)]			-
Male	34(69.3)	34(59.6)
Female	15(30.6)	23(40.3)
BMI, median (range), kg/m²	23 ± 12	23 ± 12	-
No of injection,s median (range)	48(24)	24(62)	0.004	1.042 (1.013- 1.072)
Tolerability, [n(%)]	49(100)	43(75.4)	0.004	1.042 (1.013- 1.072)
*Adjusted No of injections ,mean ± SEM	37.28 ± 1.74	35.14 ± 1.63	-
Viral load median, IU/mL	432,210	738,902	-
^aAST median (range), μkat/L	1.66(4.23)	1.28(4.2)	-
^bALT median (range), μkat/L	1.78(5.47)	2.091(5.62)	-
Albumin median (range), g/L	39 ± 20	39 ± 10	-
Bilirubin median (range), μmol/L	15.39 ± 50.44	13.6 ± 25.6	-
Hemoglobin median (range), g/dL	13 ± 5.6	13.8 ± 4.6	-
Platelets median (range), 10⁹/L	163(236)	170(207)	-
^cTLC mean ± SD, 10⁹/μL	6.5(1.7)	6.5(1.3)	-
Cholesterol mean ± SD, mmol/L	4.1 ± 0.86	4.2 ± 0.6	-
Glucose median (range), mmol/L	5.27 ± 3.277	5.5 ± 3.1	-
Insulin median (range), pmol/L	79.6 ± 113.2	63.5 ± 133.3	-
^dHOMA-IR median (range)	2.5 ± 5.71	2.16 ± 6.04	-
^eAFP median (range), ng/mL	3.5(29.5)	8(26.3)	0.024	0.563 (0.342- 0.928)
*Adjusted AFP, mean ± SE	3.5 ± 0.049	3.448 ± 0.045
25-OH Vitamin D mean ± SD, ng/mL	27.3 ± 9.2	21.07 ± 10.1	0.002	1.068(1.024-1.115)
IL28B rs12979860 [n(%)]			Chi² = 31.35 p < 0.001
C/C	28(57.1)	6(10.5)	<0.001	11.33(4.09-39.35)
C/T	20(40.8)	35(62.4)
T/T	1(2)	16(28.07)
T allele carriers/ T allele non carriers	21/28	51/6	<0.001	0.088(0.032-0.244)
VDR rs2228570 [n(%)]			Chi² = 8.554 p = 0.014
A/A	9(18.3)	1(1.7)	0.018	12.6(1.53-103.4)
A/G	18(36.7)	24(42.1)
G/G	22(44.8)	32(56.1)

^a AST, aspartate aminotransferase; ^b ALT, alanine aminotransferase; ^c TLC, total leukocyte count; ^d HOMA-IR, homeostatic model of insulin resistance; ^e AFP, alfa feto protein; NR, non-responders; SVR, sustained virological responders; N, number of samples; OR, odds ratio; 95%CI Confidence Interval.; Chi-square test for genotype distribution; IL28B: interleukin 28 B
*Calculated by general linear model with adjustment for tolerability

Back to article page